RxDoctor Payments Data

Rebekah Hawkins

Family · Homer, GANPI 1942779772

Payments from drug & device makers

$694in general payments, 2019–2025

Across 27 payments — averaging $25.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$117
  • AbbVie$99
  • Abbott$95
  • AstraZeneca$86
  • Exact Sciences$71
  • Lilly USA, LLC$60
  • plus $166 from 7 others

What the payments were for

  • Food & beverage$694100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$694 in reported general payments places this provider in the 60th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$676
Medicare patients
22
Services billed
30

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide31$40,564
TrulicityDulaglutide26$32,230
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$20,642
JardianceEmpagliflozin21$18,725
FarxigaDapagliflozin Propanediol11$13,770
OzempicSemaglutide12$12,577
JanuviaSitagliptin Phosphate11$10,935
Albuterol Sulfate HfaAlbuterol Sulfate67$1,549
Diclofenac Sodium38$1,162
Gabapentin71$1,135
Ezetimibe14$1,066
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$868
Trazodone Hcl78$867
Levothyroxine Sodium94$780
Omeprazole68$771

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$60$72,79457 claims
GSKTrelegy Ellipta$16$20,64217 claims
Boehringer IngelheimJardiance$27$18,72521 claims
AstraZenecaFarxiga$86$13,77011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 6,258 family providers in Georgia.

Other family in Homer

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →